Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
The Carisma Therapeutics manufacturing process will be transferred to the Novartis Cell Therapy Site in Morris Plains, NJ, in the coming days. Clinical manufacturing is planned to begin in 2023.
